Definium Therapeutics, Inc. (NASDAQ:DFTX) Given Average Recommendation of “Buy” by Analysts

Shares of Definium Therapeutics, Inc. (NASDAQ:DFTX) have been given an average recommendation of “Buy” by the twelve ratings firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, nine have assigned a buy rating and two have issued a strong buy rating on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $35.70.

A number of analysts have recently weighed in on the stock. HC Wainwright increased their price objective on shares of Definium Therapeutics from $55.00 to $70.00 and gave the stock a “buy” rating in a research note on Monday, March 2nd. Robert W. Baird set a $37.00 target price on shares of Definium Therapeutics in a research report on Thursday, January 29th. Royal Bank Of Canada upped their price target on shares of Definium Therapeutics from $20.00 to $36.00 and gave the company an “outperform” rating in a report on Friday, January 23rd. Jefferies Financial Group initiated coverage on Definium Therapeutics in a research report on Thursday, January 29th. They set a “buy” rating and a $30.00 price target on the stock. Finally, Needham & Company LLC reiterated a “buy” rating on shares of Definium Therapeutics in a research note on Monday, January 5th.

Insider Buying and Selling

In related news, insider Mark Sullivan sold 11,276 shares of the firm’s stock in a transaction dated Friday, December 26th. The stock was sold at an average price of $13.15, for a total transaction of $148,279.40. Following the sale, the insider directly owned 282,576 shares of the company’s stock, valued at $3,715,874.40. This trade represents a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Daniel Karlin sold 5,600 shares of Definium Therapeutics stock in a transaction that occurred on Friday, December 26th. The shares were sold at an average price of $13.15, for a total value of $73,640.00. Following the transaction, the insider owned 425,025 shares of the company’s stock, valued at approximately $5,589,078.75. This represents a 1.30% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 42,667 shares of company stock valued at $561,071 over the last ninety days. Company insiders own 2.26% of the company’s stock.

Hedge Funds Weigh In On Definium Therapeutics

Institutional investors have recently made changes to their positions in the company. Royal Bank of Canada lifted its stake in shares of Definium Therapeutics by 10.4% in the 1st quarter. Royal Bank of Canada now owns 65,237 shares of the company’s stock valued at $382,000 after purchasing an additional 6,148 shares during the period. Teacher Retirement System of Texas grew its position in Definium Therapeutics by 9.4% during the second quarter. Teacher Retirement System of Texas now owns 16,260 shares of the company’s stock valued at $106,000 after buying an additional 1,400 shares during the period. Geode Capital Management LLC increased its holdings in Definium Therapeutics by 4.0% in the second quarter. Geode Capital Management LLC now owns 1,733,454 shares of the company’s stock valued at $11,252,000 after buying an additional 66,663 shares in the last quarter. Creative Planning increased its holdings in Definium Therapeutics by 2.6% in the second quarter. Creative Planning now owns 66,097 shares of the company’s stock valued at $429,000 after buying an additional 1,655 shares in the last quarter. Finally, Persistent Asset Partners Ltd acquired a new position in shares of Definium Therapeutics in the second quarter worth about $238,000. 27.91% of the stock is owned by hedge funds and other institutional investors.

Definium Therapeutics Price Performance

Shares of NASDAQ:DFTX opened at $19.05 on Wednesday. Definium Therapeutics has a twelve month low of $4.70 and a twelve month high of $19.62. The company’s 50 day moving average is $16.30 and its 200 day moving average is $13.25. The company has a current ratio of 6.29, a quick ratio of 6.29 and a debt-to-equity ratio of 0.12. The company has a market cap of $1.88 billion, a PE ratio of -8.94 and a beta of 2.56.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.